CA-STARCITY
23.12.2020 17:02:14 CET | Business Wire | Press release
Starcity, one of the fastest-growing technology enabled real estate owners and operators, announced today the launch of invest.starcity.com . This first of its kind investment platform allows accredited investors the opportunity to back Starcity development projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201223005265/en/
"We are thrilled to launch invest.starcity.com , so investors of all kinds have the opportunity to back Starcity developments. Typically, large-scale institutional investments are reserved for closed-door dealings, and we're excited to open these deals up to democratize access for more people," said Jon Dishotsky, CEO and co-founder of Starcity.
The first project will be Starcity Minna, a fully approved, 16-story, 270 unit, highrise in the South of Market (SoMa) district of San Francisco. Starcity will operate the 122,845 gross square feet development as a furnished residential community targeting middle and low-income residents of San Francisco with a convenient, value-oriented, and highly amenitized residential lifestyle offering.
"Despite the fall in rents in San Francisco this past year, the city remains largely out of reach for working-class professionals. Very few individuals can afford a $3,000 to $4,000 apartment, and we're excited to deliver units that start in the $900-$1,000 range. This level of affordability has rarely been achieved in San Francisco. Furthermore, major investors and occupiers like Amazon, Blackstone, Google, KKR, Starwood, and others have announced investment initiatives into San Francisco during the pandemic, and Brookfield is going vertical on projects right next door to Minna, so the time is right. And despite noise in the headlines, San Francisco has been a consistently above-market return investment geography due to the supply constraints and demand drivers," said Mo Sakrani, Chief Investment Officer and co-founder of Starcity.
Starcity Minna will comprise 15 residential levels over a welcoming ground floor lobby and event space attached to an outdoor patio, as well as a bike repair and storage facility. Each residential level (FL 2-16) hosts 18 private units with ensuite bathrooms and features a 1,000 square feet amenity space that includes a chef's-style kitchen and dining area, lounge, and media area with expansive city views. The building is topped by a large landscaped rooftop terrace, offering panoramic views of San Francisco.
Starcity Minna will consist of steel modules over a concrete ground-floor podium, tied-together with a concrete elevator core. Four primary module types will make up the private units, corridors, common areas, and stairs. Each module will arrive fully outfitted with furnishings, bathroom and kitchen fixtures, piping, and wiring.
Modular construction is well suited for Starcity Minna for two main reasons. First, San Francisco is one of the most expensive cities to build in globally, and modular construction shifts those costs to an off-site factory. Second, the standardized unit layout is conducive to manufacturing.
"San Francisco remains one of the strongest apartment rental markets in the country. We are delighted to provide access for individual investors into a well-located project poised to capitalize on the city’s next wave of growth and appreciation through technology powered by the Republic platform. Real estate is an $8.9 trillion market, and it's time for everybody to own a piece of it,” said Janine Yorio, Head of Real Estate at Republic.
With this new offering Starcity is reimagining the entire spectrum of real estate:
- On the investment side by allowing people access to build wealth.
- On the housing side by making living in cities accessible.
- On the construction side, by exploring modular to bring the cost of construction down.
This template should create a path for major affordable housing in any city that has income inequality that has been further exacerbated by the pandemic. Real estate has long been a stodgy investment industry, designed to keep the main street investor out — Starcity aims to change that with this launch.
Starcity is one of the leading coliving companies and operates over 1,500 units globally, with over 3,000 units in its development and operations pipeline throughout North America and Western Europe and over 10,000 units in negotiations. Starcity is backed by Y Combinator, NEA, Social Capital, Tribe Capital, Bullpen Capital, Deciens, and Industry Ventures.
Starcity is conducting a Rule 506(c) offering solely to accredited investors. Republic Real Estate has provided the technology to enable Invest.starcity.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005265/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
